What is the rationale for combining basal insulin plus GLP-1 RA into a fixed ratio formulation? How does this impact pan-glycemic--FPG and PPG--control and other target goals and risk factors?

What is the rationale for combining basal insulin plus GLP-1 RA into a fixed ratio formulation? How does this impact pan-glycemic--FPG and PPG--control and other target goals and risk factors?

What is the rationale for combining basal insulin plus GLP-1 RA into a fixed ratio formulation? How does this strategy impact pan-glycemic—FPG and PPG—control and other metabolic target goals and risk factors?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Pablo Mora, MD

Pablo Mora, MD

Diabetes America
Staff Endocrinologist
Division of Endocrinology, Diabetes and Metabolism
University of Texas Southwestern Medical Center
Plano, Texas